Ghrelin
Also known as: Hunger hormone, Growth hormone secretagogue peptide, GHS-R1a ligand
Overview
Ghrelin is a 28-amino acid acylated peptide hormone produced primarily by X/A-like cells of the gastric fundus. It is the endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a), stimulating GH release, appetite, and gastric motility. As the only known circulating orexigenic (appetite-stimulating) hormone and the endogenous counterpart to synthetic GHS-R1a agonists like GHRP-2, GHRP-6, Ipamorelin, and MK-677, ghrelin occupies a central position in metabolic and GH physiology research. Its unique octanoyl group modification at Ser3 is essential for GHS-R1a binding.
Mechanism of Action
Acylated ghrelin (the active form, octanoylated at Ser3 by ghrelin O-acyltransferase/GOAT enzyme) binds GHS-R1a (GHSR) on pituitary somatotrophs, triggering Gq-mediated phospholipase C activation, IP3-mediated calcium release, and GH secretion. In the hypothalamus, ghrelin activates NPY/AgRP neurons while suppressing POMC neurons, powerfully stimulating appetite. In the gastrointestinal tract, ghrelin via GHS-R1a promotes gastric motility and acid secretion. Ghrelin levels rise markedly before meals (promoting hunger) and fall post-meal. Des-acyl ghrelin (without octanoyl group) has distinct biological activities via non-GHS-R1a receptors.
Potential Benefits
- Endogenous GH secretagogue (natural GH pulse driver)
- Understanding ghrelin enabled development of all GHS-R1a agonist drugs
- Research target for anti-obesity drugs (ghrelin antagonists)
- Gastroparesis treatment target (promotes gastric motility)
- GH deficiency and cachexia therapeutic target
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Research/clinical only — not a consumer peptide |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Research protocols: hours to days |
Endogenous appetite hormone. Therapeutics target ghrelin pathway (GHRPs are synthetic mimetics).
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intravenous (research) 100%
Primary research route.
Subcutaneous Moderate — rapidly degraded
Acylated ghrelin requires stable formulation.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Ghrelin:
Research Context Only
Endogenous ghrelin is not used in stacking — GHRP-2/GHRP-6/Ipamorelin/MK-677 are synthetic mimetics used instead.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 0.5-1 mg (research). Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Gly-Ser-Ser(octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg
Side Effects & Safety
- Appetite stimulation (primary pharmacological effect)
- Hyperinsulinemia at pharmacological doses
- Gastric acid secretion increase
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~10-30 minutes (acylated ghrelin) |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Ghrelin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.